Introduction
Transplant-associated thrombotic microangiopathy (TA-TMA) is an increasingly recognized complication of SCT.
1 TA-TMA occurs when endothelial injury leads to microangiopathic hemolytic anemia and platelet consumption, resulting in thrombosis, fibrin deposition in the microcirculation and organ impairment. 2, 3 TA-TMA is commonly reported following allo-SCT. [4] [5] [6] Risk factors include high-dose chemotherapy (HDC), radiation therapy (XRT), infection (notably CMV, human herpesvirus-6 and aspergillus), GVHD and use of calcineurin inhibitors. 3, [7] [8] [9] Treatment of TA-TMA has included withdrawal of offending agents, plasmapheresis, 10 rituximab 11 and defibrotide. 12 However, responses are variable and often unsatisfactory and mortality rates can approach 60%. 3, 13 TA-TMA is less commonly reported following auto-SCT. 4, 14, 15 In the pediatric population, HDC followed by auto-SCT is the standard treatment for high-risk neuroblastoma. 16 Neuroblastoma presents a unique opportunity to study TA-TMA because of standardized chemotherapy regimens and the absence of GVHD. The need to administer XRT and cis-retinoic acid (cis-RA) after SCT makes the identification and management of TA-TMA essential for optimal therapy. 16 The diagnosis of TA-TMA is challenging because it occurs in a population already at independent risk for hematological abnormalities. 17, 18 We conducted a casecontrol study of TA-TMA in pediatric neuroblastoma patients receiving auto-SCT to evaluate early clinical indicators of TA-TMA.
Methods
This study was approved by the institutional review board. We performed a case-control analysis by retrospectively reviewing the charts of all patients with high-risk neuroblastoma receiving an auto-SCT in the past 5 years. Patients who had been diagnosed with TA-TMA during their hospital stay following SCT were assigned to the 'TMA-group' during our chart review. TA-TMA diagnosis was consistent with published guidelines. 18, 19 Criteria included intravascular hemolysis with microangiopathic signs of acute anemia, elevated lactate dehydrogenase (LDH), schistocytes on peripheral blood smear, negative Coombs test, low haptoglobin, persistent thrombocytopenia and acute kidney injury. Given the high risk of renal biopsy in the SCT population, biopsy was not required for diagnosis, but was included if available.
The demographic and treatment characteristics of the cohort are shown in Table 1 . All patients were treated on or according to national protocols. Six cycles of induction chemotherapy were given according to the Children's Oncology Group protocols A3973 (cycle 1, 2, 4 and 6: VCR, CY, doxorubicin; cycle 3, 5: etoposide, cisplatin) and ANBL0532, regimen A (cycle 1, 2: CY, topotecan; cycle 3, 5: etoposide, cisplatin; cycle 4, 6: VCR, CY, doxorubicin). Owing to poor disease response, three patients in the non-TMA-group received one to three additional courses of topotecan and CY chemotherapy as per protocol A3973 between induction and auto-SCT. Two of these patients proceeded to the new approaches to neuroblastoma therapy (2001-2002) study for consolidation that included 131 I-Metaiodobenzylguanidine therapy on day -21 before auto-SCT. In accordance with standard protocols, patients received local XRT starting not earlier than 28 days post transplant.
HDC started on day -7 and autologous PBSCs were infused on day 0. All patients received a single transplant with high dose carboplatin (day -7 through -4), etoposide (day -7 through -4) and melphalan (day -7 thought -5). HDC in one patient was dosed per kilogram of body wt because of small size (10 kg), whereas the remaining 19 were dosed by body surface area (m 2 ). One 16-year-old obese patient (149 kg) in the non-TMA-group had chemotherapy dosed by adjusted body wt. One patient in the non-TMAgroup treated with 131 I-Metaiodobenzylguanidine had a HDC dose adjustment for a glomerular filtration rate (GFR) of 80 mL/min per 1.73m 2 . There were no other dose adjustments.
Transplant-related supportive care and monitoring was according to institutional guidelines and uniform for all patients. Transfusion criteria were a hemoglobin o8 gm/ 100 mL and a platelet count o10 Â 10 9 /L. Platelet transfusion parameters were increased to 50 Â 10 9 /L with clinical bleeding. Platelet engraftment was defined as a platelet count 420 Â 10 9 /L for three consecutive days without transfusions.
Laboratory and clinical data were abstracted for 30 days before and 30 days after auto-SCT, as most of our TA-TMA cases occurred in the first month after auto-SCT. The same data points were captured if TA-TMA was diagnosed more than 30 days post transplantation.
Laboratory data included hemoglobin, platelet count, LDH, presence of schistocytes on peripheral blood smear, Coombs test, haptoglobin, serum creatinine, serum albumin and urinalysis findings. Patients had LDH and haptoglobin checked because of the concern for hemolytic anemia with schistocytes and the concern for TA-TMA due to significant hypertension requiring multiple anti-hypertensives. Hematuria was defined as 45 RBC per highpowered field. Proteinuria was defined as a sulfosalicylic acid precipitate X1 þ on at least two separate samples. Random urine protein-to-creatinine ratios were reported if available. Pre-transplant nuclear GFR (nucGFR, technetium-99 m-DTPA) was performed after the last course of induction chemotherapy and within 30 days of auto-SCT. Post transplant nucGFR was performed before XRT at approximately 30-40 days post transplantation. The Schwartz formula, 20 using an updated formula of 0.413*(height per serum creatinine), was also used as an additional measure of GFR during the data analysis. 21 Some patients in the TMA-group had ADAMTS13 checked before starting therapy for TA-TMA. Complement (C 0 ) gene sequencing and functional studies were conducted after the resolution of TA-TMA to evaluate a potential underlying cause. Clinical data included systolic and diastolic blood pressure measurements performed by dynamap every 4 h during inpatient stays or at clinic visits for 30 days before and after auto-SCT. Blood pressure measurements were transformed to standardized blood pressure indices. An index value is the patient's blood pressure divided by their ninety-fifth percentile value for age, sex and height. Therefore, an index X1 equals hypertension. 23 Antihypertensive medications, n of packed red blood cell and platelet transfusions, infections, antimicrobial medications and transplant complications were also recorded.
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Statistical Analysis was performed using SAS, version 9.2 (SAS Institute, Cary, NC, USA). Data were assumed not to deviate from a normal distribution on the basis of examination of tests for skewness and normal P plots generated with univariate analysis. Continuous variables were analyzed using Student's t-test and Wilcoxon rank sum, as appropriate. Post transplant continuous variables were analyzed using generalized linear models in order to control for pre-transplant values, when available. Categorical variables were compared using w 2 Fischer's exact test, dependent upon marginal distributions. Statistical significance was defined as an alpha of o0.05.
Results

Baseline characteristics
We identified 22 consecutive patients with high-risk neuroblastoma undergoing auto-SCT. Two patients were excluded from the analysis. The first patient died from severe veno-occlusive disease of the liver (VOD) on day þ 13 after 131 I-Metaiodobenzylguanidine therapy and transplantation. The second patient, who had a history of renal artery ligation during tumor surgery, developed acute renal failure requiring short-term hemodialysis on day -3 of HDC. The remaining 20 patients were included in the analysis. Of these, 6 patients had TA-TMA and the 14 patients who did not served as controls.
There were no significant differences in patient demographics, disease characteristics or induction chemotherapy between the two groups ( Table 1) . Pre-and post transplant complications (not due to TA-TMA) were comparable in both groups (Supplement 1). No study patient developed bacteremia, veno-occlusive disease of the liver or TRM.
Patients were diagnosed with TA-TMA a median of 20 days (range 8-109 days) after SCT. Four patients were diagnosed with TA-TMA by day þ 25 (before receiving XRT) and 2 patients were diagnosed after completion of post transplant local XRT (on days þ 90 and þ 111, respectively). Reactivation of viral infections coincided with signs of early onset TA-TMA in two patients (Table 2) .
Hematological findings
Patients diagnosed with TA-TMA had laboratory findings consistent with microangiopathic hemolytic anemia. Schistocytes were universally detected in the TMA-group (n ¼ 6) in comparison to only one patient in the non-TMA-group (P ¼ 0.0002) ( Table 3) . Five of six TMA-group patients There was no statistical difference in average daily hemoglobin, platelet count or transfusion requirements between the groups (Table 3 ). In the study cohort as a whole, each patient required approximately five packed red blood cell transfusions and 21 platelet transfusions after SCT. Non-TMA-group patients had platelet engraftment by day 32 ± 2.1. In contrast, three patients with severe TA-TMA remained platelet transfusion-dependent for more than 120 days post transplant. After resolution of TA-TMA, two patients recovered platelet counts by 33 and 74 days after SCT, respectively. One patient in the TMA group was already engrafted with platelets when TA-TMA was incidentally diagnosed on day þ 111 by hypertension, new onset anemia and thrombocytopenia. There were no abnormalities detected in ADAMTS13 or C 0 studies (Supplement 2).
Renal findings
Renal parameters of patients are summarized in Table 4 . Patients in both groups had an average GFR 4100 mL/min per 1.73m 2 within 30 days before auto-SCT. One patient in the non-TMA-group was diagnosed with tumor-related hypertension at neuroblastoma diagnosis and required therapy with nifedipine and labetalol only during the first month of induction chemotherapy. Otherwise, pre-SCT blood pressure readings were normal in all patients and not statistically different between the groups.
Despite receiving multiple anti-hypertensive medications (Table 2 ), blood pressure during the 30 days after auto-SCT was significantly higher in patients with TA-TMA compared with the non-TMA-group (Table 4) . Compared with controls, significant increases in the average systolic blood pressure of TA-TMA patients was already evident on day -3, that is, during HDC and before stem cell infusion ( Figure 1) . Similarly, significant increases in the average diastolic blood pressure of patients who went on to Table 3 Hematologic parameters during the first 30 days after auto-SCT
Schistocytes present 6 (100%) 1 (7.1%) 0.0002 Hemoglobin (g/100 mL) develop TA-TMA were apparent on day -7 (not shown).
All patients in the TMA-group required significant antihypertensive therapy compared with the control group. Although hypertension in the non-TMA-group was treated briefly with only diuretics (n ¼ 3), TMA group patients required three to six anti-hypertensive medications in addition to diuretic therapy (Table 2) . Post transplant proteinuria and hematuria were also significant indicators of TA-TMA. Almost all of our patients had pre-transplant (n ¼ 18/20) and post transplant (n ¼ 19/20) urinalyses performed. Only one patient (non-TMA-group) had proteinuria (trace to 3 þ sulfosalicylic acid) before transplant, which resolved within the first month of SCT. Five of six TMA patients had severe proteinuria, with an average urine protein (mg/100 mL) to creatinine (mg/100 mL) ratio of 14.8 (range of 5.5-32.5, normal o0.2). Patient #6 was not tested. Despite significant proteinuria, serum albumin remained normal in the TMA-group and was not different from the non-TMAgroup.
During the 30 days after transplantation, serum creatinine remained similar and within normal limits in both groups. However, in the TMA-group, the nucGFR decreased by 60% from baseline. During the same evaluation period, the nucGFR decreased by 25% from baseline in the non-TMA-group, but still remained within the normal range (4100 mL/min per 1.73m 2 ) ( Table 4) . In three patients, a kidney biopsy was performed after careful assessment of the risk-benefit ratio of this procedure. Essentially, it was felt that the information obtained with a biopsy (for example, extent of acute, and thus potentially reversible, vs chronic histological changes) would likely guide important treatment decisions and the biopsy could be performed with reasonable safety (for example, with a manageable platelet count). As illustrated in Figure 2 , all three biopsies showed diagnostic findings of TA-TMA.
TA-TMA complications and therapy
All patients with TA-TMA had clinically significant hypertension that required aggressive treatment with three to eight medications ( Table 2) . Three of six patients developed severe polyserositis at diagnosis of TA-TMA, two of which coincided with refractory viremia (adenoviral and CMV). Five of six patients were treated with 2 to 10 weekly doses of rituximab (375 mg/m 2 IV). After a therapeutic trial with 4 weekly doses of rituximab, three patients received plasmapheresis starting 27-59 days after diagnosis of TA-TMA. Daily plasmapheresis was continued until resolution of microangiopathy and then slowly tapered off. Patient #6 developed TA-TMA after returning to the referring institution post transplantation and did not receive any TA-TMA targeted therapy.
The three patients with the most severe TA-TMA (#1, 4, 6) remain with chronic hypertension. One patient is on chronic hemodialysis due to end-stage renal disease. Cis-RA therapy was completely omitted in these patients due to renal dysfunction. The other three patients (#2, 3 and 5) responded well to therapy and had resolution of hypertension, but one remained with a nucGFR o70 mL/min per 1.73m 2 . With close clinical monitoring, these three patients received partial therapy with cis-RA by starting at 25% of recommended dosing and escalating slowly ( Table 2) .
Discussion
In this study, neuroblastoma patients with TA-TMA and controls were nearly identical by multiple clinical criteria before auto-SCT, suggesting limitations in the ability to predict which patients will go on to develop TA-TMA after HDC and auto-SCT. Therefore, our aim was to identify clinical measures that would allow the early diagnosis of TA-TMA in an attempt to prevent complications.
Of note, and as shown in Figure 1 , we found elevated blood pressure levels to be an early clinical indicator of TA-TMA risk: compared with controls, patients who later developed TA-TMA already showed significantly higher systolic and diastolic blood pressure during HDC and before stem cell infusion. Systolic and diastolic hypertension were evident on average by 13 and 14 days after auto-SCT, respectively, and persisted despite anti-hypertensive therapy, confirming the observations by Hale et al.
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Expanding their findings, we also documented early, 'prehypertensive' elevations in blood pressure in patients who eventually developed TMA, implying that HDC itself may trigger endothelial damage and subsequent full-blown TA-TMA in susceptible individuals. Nephrotic-range proteinuria and hematuria were also significant signs of TA-TMA.
We believe that careful attention to blood pressure and simple urinalysis findings in the peri-and immediate post transplant period may expedite the diagnosis of TA-TMA Compared with the non-TMA-group, average systolic blood pressure levels in the TA-TMA group were significantly higher on day -3 of HDC and thus already before stem cell infusion. Systolic hypertension was apparent by day þ 13 (about 1 week before the diagnosis of TA-TMA, at a median of 20 days after SCT) and persisted despite aggressive anti-hypertensive therapy (Table 2 ).
in neuroblastoma patients undergoing auto-SCT. These findings are supported by current pediatric guidelines on diarrhea-negative hemolytic uremic syndrome. 25 Hale et al., 24 reported hypertension in 21 of 28 (75%) pediatric patients with TA-TMA after allo-SCT. Patients in their retrospective study were also receiving TBI and CsA, an agent known for its association with hypertension and TA-TMA. In contrast, none of the patients in our study treated with auto-SCT for neuroblastoma had medications or other clinical conditions that are known to cause hypertension.
We also observed a dramatic reduction in renal function as measured by nucGFR in patients developing TA-TMA, again in accordance with previous observations. 24 Conversely, neither serum creatinine nor Schwartz GFR post transplantation differed between those with and without TA-TMA. This supports the theory that creatinine, and creatinine-based GFR calculations, are poor markers of kidney function in this population, as they can remain in the normal range until there is quite significant renal dysfunction. 24 This observation is not surprising as creatinine is highly dependent on muscle mass, which may be substantially reduced in chronically ill populations, such as the one studied here. Whether kidney function measures that are less complicated to perform than nucGFR, but provide equivalent sensitivity, for example, cystatin C determinations, 26 can be introduced in the pediatric SCT population is currently under investigation at our center.
Two guidelines have been published to assist in the diagnosis of TA-TMA. Both guidelines support the use of hematological criteria, and one incorporates renal and neurological dysfunction. 18, 19 Our patients fit the published diagnostic criteria for TA-TMA due to the presence of schistocytes, elevated LDH, renal dysfunction, negative Coombs test and decreased haptoglobin. Contrary to Ruutu et al., 19 we did not find that thrombocytopenia, anemia or transfusion requirements could differentiate TMA-group from non-TMA-group patients. Transfusions for other clinical conditions after SCT, such as hemorrhagic mucositis, could mask anemia and thrombocytopenia, supporting the difficulty of using these hematologic parameters to diagnose TA-TMA. 4, 17, 18 TA-TMA is associated with significant morbidity and mortality. 3, 8, 27 The disease is particularly problematic in neuroblastoma because renal dysfunction and hypertension may prevent radiation and cis-RA therapy. As the addition of cis-RA significantly improves survival in high-risk neuroblastoma, the inability to receive this therapy adversely affects outcome. 16 TA-TMA is less commonly reported following autologous compared with allogeneic SCT, possibly because of the absence of GVHD and of prophylaxis against it with calcineurin inhibitors. [4] [5] [6] Nevertheless, we identified a 30% prevalence of TA-TMA after auto-SCT in a pediatric neuroblastoma population receiving standardized HDC. Two previous studies in neuroblastoma reported a similarly high prevalence, but most patients had received TBI, a known risk factor for TA-TMA. 14, 15 The majority of our cases developed TA-TMA before XRT, with only two patients (33%) receiving local XRT (which included part of the kidney) before the diagnosis of TA-TMA. Although the etiology for TA-TMA in auto-SCT remains to be determined, platinum-based chemotherapy, viral infections and XRT to the kidney are likely risk factors. 3, [7] [8] [9] 28 Current therapy for TA-TMA is suboptimal. Our incomplete understanding of its etiology and pathogenesis, along with non-standardized diagnostic criteria, limits the systematic evaluation of therapies in TA-TMA. 1, 5, 29 Options include removing causative agents, such as calcineurin inhibitors (which is not applicable in auto-SCT), and using plasmapheresis, steroids, rituximab and defibrotide. None of these treatments have produced consistently beneficial results. 3, 13 The general consensus in the literature is that plasmapheresis is not effective in TA-TMA. However, this conclusion may be biased because patients are usually diagnosed late and may have already suffered significant or irreversible vascular damage. Some reports in the literature note the potential benefit of early intervention. 1, 8 Similar to findings in the literature, we report normal ADAMTS13 levels in TA-TMA patients. 4, 8 Susceptible patients may have disturbances in the C 0 cascade, contributing to endothelial damage. 22, 30 It is possible that the beneficial effects of early plasmapheresis in some patients might be attributable to correction of C 0 abnormalities or to the elimination of cytokines causing acute endothelial damage. 31, 32 Although none of our patients had an identifiable C 0 abnormality, it is important to note that C 0 studies were performed after resolution of TA-TMA. Others have also reported normal C 0 levels and activity in their TA-TMA patients. 24 It is unclear whether we would have found different results if these measurements would have been made during acute TA-TMA.
We acknowledge that any retrospective analysis may be limited by the possibility of bias. Even though only half of our cases were biopsy-proven, we feel misclassification is unlikely as the microangiopathic changes, significant hypertension, proteinuria and renal failure identified in the TMA-group were absent in controls. Furthermore, our statistical analysis was limited by the fact that only patients with suspected TA-TMA had hemolysis parameters measured. Prospective studies are needed to better define the diagnostic role of LDH and haptoglobin in this population.
Our study adds to the literature by increasing the awareness for TA-TMA in the pediatric neuroblastoma population and by suggesting simple targeted monitoring for these patients. As blood pressure and urinalyses are routinely followed, careful attention to evolving hypertension and proteinuria can aid in the early diagnosis of TA-TMA. These findings need to be confirmed in larger, prospective studies, hopefully leading to better diagnostic and therapeutic approaches to this significant complication.
